Bazedoxifene Acetate

ApprovedSmall molecule

Pfizer

Bazedoxifene Acetate is one of 85 small molecule programs targeting Multiple Sclerosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

OsteoporosisActive, not recruiting

SchizophreniaActive, not recruiting

Multiple SclerosisPhase 2

Active, not recruiting

OsteoporosisPhase 3

Active, not recruiting

SchizophreniaApproved

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Bazedoxifene Acetate

Pfizer

Approved

1 2

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 3

Depakote

Lunesta

3 5

Luvox

SSolvay Pharmaceuticals

Preclinical

1 6

Catapres

Boehringer Ingelheim

Preclinical

1 7

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

1 8

Persantine

Boehringer Ingelheim

Preclinical

1 9

Permax

VValeant Pharmaceuticals

Preclinical

1 10

Orap

Teva

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoporosis2 trials

Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women

Completed· Pfizer logo

Pfizer·Phase 3·NCT00205777·7,609 enrolled

Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women

Completed· Pfizer logo

Pfizer·Phase 3·NCT00481169·1,742 enrolled

Schizophrenia1 trial

Bazedoxifene -Treatment for Women With Schizophrenia

Unknown status·TThe Alfred·Phase 4·NCT04113993·160 enrolled

Multiple Sclerosis1 trial

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

Completed·—·Phase 2·NCT04002934·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Bazedoxifene Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bazedoxifene Acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bazedoxifene Acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Bazedoxifene Acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoporosis2 trials

Schizophrenia1 trial

Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News